Phase I
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 24, 2020.
Francis Collins, the director of the NIH, told STAT they were “really well-powered, rigorously designed clinical trials.”
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 22, 2020.
AstraZeneca’s COVID-19 vaccine candidate induced significant immune responses in the majority of patients following a single dose in a Phase I study. The preventative medication also proved to be fairly safe, study results showed.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 20, 2020.
It was a surprisingly big week for clinical trial updates related to COVID-19, although there was plenty of non-COVID-19 news as well. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 17, 2020.
AC Immune, based in Lausanne, Switzerland, initiated the second highest dosing group in its Phase Ib/IIa clinical trial of ACI-35.030 for Alzheimer’s disease. The move is based on encouraging interim data from the initial dosing cohort.
Phase I data from the COVID-19 vaccine under development by AstraZeneca and Oxford University’s Jenner Institute is showing a robust defense against the novel coronavirus that has infected more than 13 million people across the globe.
PRESS RELEASES